Abhishek Bhat1, Chad R Ritch1,2. 1. Department of Urology, University of Miami, Miller School of Medicine. 2. Department of Urologic Oncology, Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
Abstract
PURPOSE OF REVIEW: To provide a current comprehensive review of the available urinary biomarkers for the detection and surveillance of bladder cancer. RECENT FINDINGS: The limitations of urine cytology and invasive nature of cystoscopic evaluation have led to a growing search for an ideal, cost-effective biomarker with acceptable sensitivity and specificity. Current FDA approved biomarkers such as UroVysion fluorescent in situ hybridization, Immunocyt, and nuclear matrix protein 22 do not have the specificity, and thus positive predictive value to warrant their cost as a routine adjunct or replacement for cystoscopy. Several promising commercially available assays such as Cxbladder, Assure MDx, and Xpert BC may perform better than cytology in select populations. Novel genomic, epigenetic, inflammatory, and metabolomic-based assays are being analyzed as potential urinary biomarkers. SUMMARY: Urinary biomarkers with high sensitivity and specificity are an unmet need in bladder cancer. Several new assays may meet these criteria and future research may justify use in clinical practice.
PURPOSE OF REVIEW: To provide a current comprehensive review of the available urinary biomarkers for the detection and surveillance of bladder cancer. RECENT FINDINGS: The limitations of urine cytology and invasive nature of cystoscopic evaluation have led to a growing search for an ideal, cost-effective biomarker with acceptable sensitivity and specificity. Current FDA approved biomarkers such as UroVysion fluorescent in situ hybridization, Immunocyt, and nuclear matrix protein 22 do not have the specificity, and thus positive predictive value to warrant their cost as a routine adjunct or replacement for cystoscopy. Several promising commercially available assays such as Cxbladder, Assure MDx, and Xpert BC may perform better than cytology in select populations. Novel genomic, epigenetic, inflammatory, and metabolomic-based assays are being analyzed as potential urinary biomarkers. SUMMARY: Urinary biomarkers with high sensitivity and specificity are an unmet need in bladder cancer. Several new assays may meet these criteria and future research may justify use in clinical practice.
Authors: Jan Gleichenhagen; Christian Arndt; Swaantje Casjens; Carmen Töpfer; Holger Gerullis; Irina Raiko; Dirk Taeger; Thorsten Ecke; Thomas Brüning; Georg Johnen Journal: PLoS One Date: 2022-06-29 Impact factor: 3.752
Authors: Thomas Mandel Clausen; Gunjan Kumar; Emilie K Ibsen; Maj S Ørum-Madsen; Antonio Hurtado-Coll; Tobias Gustavsson; Mette Ø Agerbæk; Francesco Gatto; Tilman Todenhöfer; Umberto Basso; Margaret A Knowles; Marta Sanchez-Carbayo; Ali Salanti; Peter C Black; Mads Daugaard Journal: Cell Death Discov Date: 2020-07-27
Authors: Michael Rose; Sarah Bringezu; Laura Godfrey; David Fiedler; Nadine T Gaisa; Maximilian Koch; Christian Bach; Susanne Füssel; Alexander Herr; Doreen Hübner; Jörg Ellinger; David Pfister; Ruth Knüchel; Manfred P Wirth; Manja Böhme; Edgar Dahl Journal: Int J Mol Sci Date: 2020-02-07 Impact factor: 5.923